Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | SLC6A1 | P30531 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23551811 | 1.00 | KCNK3 (0.54) | KCNK3LMNASMN1; SMN2SLC6A1CYP3A4 | |
| SCHEMBL28148146 | 1.00 | KCNK3 (0.54) | KCNK3LMNASMN1; SMN2SLC6A1CYP3A4 | |
| SCHEMBL28152186 | 0.98 | KCNK3 (0.52) | KCNK3LMNASMN1; SMN2SLC6A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL28151982 | 0.98 | KCNK3 (0.52) | KCNK3LMNASMN1; SMN2SLC6A1CYP3A4 | |
| SCHEMBL5226944 | 0.98 | KCNK3 (0.52) | KCNK3LMNASMN1; SMN2SLC6A1CYP3A4 | |
| SCHEMBL3145758 | 0.94 | LMNA (0.48) | KCNK3LMNASMN1; SMN2SLC6A1NR1I2 | |
| SCHEMBL1887364 | 0.94 | LMNA (0.48) | KCNK3LMNASMN1; SMN2SLC6A1NR1I2 | |
| SCHEMBL1887361 | 0.94 | LMNA (0.48) | KCNK3LMNASMN1; SMN2SLC6A1NR1I2 | |
| Hydrochloric Acid SCHEMBL9155039 | 0.93 | LMNA (0.47) | KCNK3LMNASMN1; SMN2SLC6A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL9155025 | 0.93 | LMNA (0.47) | KCNK3LMNASMN1; SMN2SLC6A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235864-A1 | COATED NEEDLE ADMINISTRATION SYSTEMS | EVOLUS, INC. (US) | 2025-11-13 | — | — | WO | claimed |
| CN-113735760-B | Preparation method of ropivacaine hydrochloride | 扬子江药业集团江苏海慈生物药业有限公司 | 2023-08-01 | — | — | CN | claimed |
| CN-113735760-A | Preparation method of ropivacaine hydrochloride | 扬子江药业集团江苏海慈生物药业有限公司 | 2021-12-03 | — | — | CN | claimed |
| US-20130046077-A1 | DOLASTATIN 15 DERIVATIVES | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2013-02-21 | — | — | US | claimed |
| US-20100099843-A1 | DOLASTATIN 15 DERIVATIVES | ABBOTT GMBH & CO. KG (DE) | 2010-04-22 | — | — | US | claimed |
| CN-113735760-B | Preparation method of ropivacaine hydrochloride | 扬子江药业集团江苏海慈生物药业有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-113735760-A | Preparation method of ropivacaine hydrochloride | 扬子江药业集团江苏海慈生物药业有限公司 | 2021-12-03 | — | — | CN | disclosed |
| CN-106928127-B | Substituted piperidine amide derivative, preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2021-07-16 | — | — | CN | disclosed |
| CN-106699744-B | Heterocyclic amide derivative, preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2021-05-11 | — | — | CN | disclosed |
| CN-106928126-B | Amide derivative, preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2019-12-20 | — | — | CN | disclosed |
| CN-105517993-B | Aryl amide kinase inhibitors | 百时美施贵宝公司 | 2018-07-13 | — | — | CN | disclosed |
| CN-108218846-A | New solid-state form of thiophene derivant and its preparation method and application | 四川海思科制药有限公司 | 2018-06-29 | — | — | CN | disclosed |
| EP-0991658-B1 | DOLASTATIN 15 DERIVATIVES | ABBOTT GMBH & CO KG (DE) | 2005-12-28 | — | — | EP | disclosed |
| US-6458765-B1 | POLYPEPTIDES AS ANTICANCER AGENTS AND AGAINST CELL PROLIFERATION | BASF AKTIENGESELLSCHAFT (DE) | 2002-10-01 | — | — | US | disclosed |
| US-6143721-A | FOR TREATING CANCER IN MAMMALS | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-07 | — | — | US | disclosed |
| EP-0991658-A1 | DOLASTATIN 15 DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2000-04-12 | — | — | EP | disclosed |
| WO-1999003879-A1 | DOLASTATIN 15 DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 1999-01-28 | — | — | WO | disclosed |
| EP-0151110-B1 | L-N-N-PROPYLPIPECOLIC ACID-2,6-XYLIDIDE AND METHOD FOR PREPARING THE SAME | Astra Läkemedel Aktiebolag (SE) | 1989-03-01 | — | — | EP | disclosed |
| EP-0151110-A1 | L-N-n-PROPYLPIPECOLIC ACID-2,6-XYLIDIDE AND METHOD FOR PREPARING THE SAME. | THURESSON AF EKENSTAM BO (SE) | 1985-08-14 | — | — | EP | disclosed |
| WO-1985000599-A1 | L-N-n-PROPYLPIPECOLIC ACID-2,6-XYLIDIDE AND METHOD FOR PREPARING THE SAME | A/S APOTHEKERNES LABORATORIUM FOR SPECIALPRAEPARAT (NO) | 1985-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099843-A1 | DOLASTATIN 15 DERIVATIVES | DDOST, DBI, DAO | KCNK3 1377/4885LMNA 891/4885SMN1; SMN2 4192/4885 |
| US-20130046077-A1 | DOLASTATIN 15 DERIVATIVES | DDOST, DBI, DAO | KCNK3 1377/4885LMNA 891/4885SMN1; SMN2 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.